
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Max CRISPR Activation Plasmid (h) | sc-400596-ACT | 20 µg | $397.00 | |||
Max CRISPR Activation Plasmid (h2) | sc-400596-ACT-2 | 20 µg | $397.00 |
Human MAX encodes Max, a basic helix–loop–helix leucine zipper transcription factor that dimerizes with MYC, MXD/MNT, and related partners to bind E-box DNA elements and regulate gene expression programs controlling cell-cycle progression, metabolism, differentiation, and apoptosis. Through MYC–MAX and MXD–MAX network dynamics, Max helps balance transcriptional activation versus repression across ribosome biogenesis, mitochondrial function, and growth signaling pathways. Perturbation of MAX can rewire oncogenic transcriptional circuitry and has been implicated in tumor-associated alterations of MYC-driven gene expression. As a nodal cofactor in chromatin-associated transcriptional regulation, MAX is frequently studied in contexts of proliferative signaling and lineage-specific transcriptional control.
Max CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous MAX expression without altering the underlying DNA sequence.
Max CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the MAX locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the MAX transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Max expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native MAX locus and enabling the study of Max-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Max pathway restoration in tumor cells with silenced or reduced MAX expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.